Novo Nordisk announced new data from the Phase 3a DUAL clinical trial comparing Xultophy (insulin degludec and liraglutide [IDegLira]) to insulin degludec (Tresiba) and liraglutide (Victoza) alone in insulin-naive and insulin-treated patients. Study results from the 52-week DUAL I and the 26-week DUAL II clinical trials were presented at the 50th European Association for the Study of Diabetes (EASD) meeting.
Findings showed that adults with type 2 diabetes treated with Xultophy resulted in rapid and substantial improvement in glycemic control with a beneficial weight profile as early as 4 weeks after initiation in both insulin-naive and insulin-treated patients. Patients treated with Xultophy also had a greater likelihood of reaching both pre-prandial and post-prandial blood glucose targets compared with either insulin degludec or liraglutide.
In DUAL I, the proportion of people achieving fasting plasma glucose ≤7.2mmol/L at Week 4 and HbA1c <7% at Week 8 was greater with Xultophy (76%; 57%, respectively) than with insulin degludec (62%; 38%) or with liraglutide (62%; 47%). At Weeks 4, 8 and 12, treatment with Xultophy also resulted in significant weight loss compared with insulin degludec, which was associated with a small overall weight gain (P<0.0001 at Weeks 4, 8, 12).>
Xultophy is a once-daily single injection that combines insulin degludec, a basal insulin analog, and liraglutide, a human glucagon-like peptide-1 (GLP-1) analog.
For more information visit NovoNordisk.com.